Just because you can manufacture a drug does not mean it is a viable, approvable commercial drug.
Professionals given incomplete data without the relevant background can be mislead like shareholders. How many professionals that don't have conflict of interest, have had the full story of the manipulated protocol/SAP, the confounding of the naïve OS, the post hoc data dredging of the recurrent GBM data. All data needs context to understand it, and NWBO has been reporting while burying things like reason for FDA partial trial stop, confounding of naïve OS data, and the trial manipulation.
What is relevant is that the regulators will see all the issues with this trial -- the protocol, endpoints, comparators and SAP, confounding the mystery FDA partial stop.
Market Data 
Markets 
AI
